Doriana Fruci

List of Publications by Year in Descending Order

74 papers	2,558 citations	26 h-index	49 g-index
81 ext. papers	3,062 ext. citations	6.6 avg, IF	4.75 L-index

#	Paper	IF	Citations
74	ERAP1 Controls the Interaction of the Inhibitory Receptor KIR3DL1 With HLA-B51:01 by Affecting Natural Killer Cell Function.. *Frontiers in Immunology*, **2021**, 12, 778103	8.4	1
73	ERAP1 as an emerging therapeutic target for medulloblastoma. *Trends in Cancer*, **2021**,	12.5	1
72	GD2 redirected CAR T and activated NK-cell-mediated secretion of IFN□overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape **2021**, 9,		4
71	Nutlin-3a Enhances Natural Killer Cell-Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors. *Cancer Immunology Research*, **2021**, 9, 170-183	12.5	10
70	ERAP1 and ERAP2 Enzymes: A Protective Shield for RAS against COVID-19?. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	6
69	Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment. *Cancers*, **2021**, 13,	6.6	5
68	Genetically driven CD39 expression shapes human tumor-infiltrating CD8 T-cell functions. *International Journal of Cancer*, **2020**, 147, 2597-2610	7.5	10
67	News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. *Seminars in Cancer Biology*, **2020**,	12.7	14
66	Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma. *Nature Communications*, **2020**, 11, 5992	17.4	28
65	Impact of Natural Occurring Single Nucleotide Polymorphisms within miRNA-Binding Sites on HCMV Infection. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
64	Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN Study. *Cancers*, **2019**, 11,	6.6	22
63	Peptide Trimming for MHC Class I Presentation by Endoplasmic Reticulum Aminopeptidases. *Methods in Molecular Biology*, **2019**, 1988, 45-57	1.4	3
62	Redundancy and Complementarity between ERAP1 and ERAP2 Revealed by their Effects on the Behcet© Disease-associated HLA-B*51 Peptidome. *Molecular and Cellular Proteomics*, **2019**, 18, 1491-1510	7.6	12
61	Regulation of ERAP1 and ERAP2 genes and their disfunction in human cancer. *Human Immunology*, **2019**, 80, 318-324	2.3	25
60	Counter-regulation of regulatory T cells by autoreactive CD8 T cells in rheumatoid arthritis. *Journal of Autoimmunity*, **2019**, 99, 81-97	15.5	18
59	Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors. *Frontiers in Immunology*, **2019**, 10, 3038	8.4	114
58	ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of □rCP. *Nature Communications*, **2019**, 10, 3304	17.4	21

57	The BET-bromodomain inhibitor JQ1 renders neuroblastoma cells more resistant to NK cell-mediated recognition and killing by downregulating ligands for NKG2D and DNAM-1 receptors. *Oncotarget*, **2019**, 10, 2151-2160	3.3	9
56	Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors. *OncoImmunology*, **2019**, 8, e1542245	7.2	8
55	Role of genetic variations on MHC class I antigen-processing genes in human cancer and viral-mediated diseases. *Molecular Immunology*, **2019**, 113, 11-15	4.3	5
54	PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma. *Clinical Cancer Research*, **2017**, 23, 4462-4472	12.9	59
53	MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma. *OncoImmunology*, **2017**, 6, e1316439	7.2	21
52	Identification of a Genetic Variation in ERAP1 Aminopeptidase that Prevents Human Cytomegalovirus miR-UL112-5p-Mediated Immunoevasion. *Cell Reports*, **2017**, 20, 846-853	10.6	16
51	The Role of HCMV and HIV-1 MicroRNAs: Processing, and Mechanisms of Action during Viral Infection. *Frontiers in Microbiology*, **2017**, 8, 689	5.7	20
50	The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress. *Cell Death and Differentiation*, **2016**, 23, 197-206	12.7	24
49	A New Insight into Pediatric Leukemia: Che-1 Involvement in Oncogenic c-Myc Signaling. *Blood*, **2016**, 128, 5267-5267	2.2	
48	Drug Transporters and Multiple Drug Resistance in Pediatric Solid Tumors. *Current Drug Metabolism* , **2016**, 17, 308-16	3.5	26
47	ERAP1 regulates natural killer cell function by controlling the engagement of inhibitory receptors. *Cancer Research*, **2015**, 75, 824-34	10.1	43
46	Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma. *OncoImmunology*, **2015**, 4, e1019981	7.2	75
45	Endoplasmic reticulum aminopeptidase 1 function and its pathogenic role in regulating innate and adaptive immunity in cancer and major histocompatibility complex class I-associated autoimmune diseases. *Tissue Antigens*, **2014**, 84, 177-86		26
44	A role for naturally occurring alleles of endoplasmic reticulum aminopeptidases in tumor immunity and cancer pre-disposition. *Frontiers in Oncology*, **2014**, 4, 363	5.3	44
43	Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma. *International Journal of Molecular Sciences*, **2013**, 14, 24706-25	6.3	69
42	High-resolution array CGH profiling identifies Na/K transporting ATPase interacting 2 (NKAIN2) as a predisposing candidate gene in neuroblastoma. *PLoS ONE*, **2013**, 8, e78481	3.7	9
41	Case-control analysis of the <i>ERAP1</i> polymorphism rs30187 in Italian type 1 diabetes mellitus patients. *Health*, **2013**, 05, 2150-2155	0.4	1
40	The putative role of endoplasmic reticulum aminopeptidases in autoimmunity: insights from genomic-wide association studies. *Autoimmunity Reviews*, **2012**, 12, 281-8	13.6	55

39	Hedgehog/hyaluronic acid interaction network in nonalcoholic fatty liver disease, fibrosis, and hepatocellular carcinoma. *Hepatology*, **2012**, 56, 1589	11.2	4
38	Role of endoplasmic reticulum aminopeptidases in health and disease: from infection to cancer. *International Journal of Molecular Sciences*, **2012**, 13, 8338-52	6.3	51
37	Epigenetic deregulation of microRNAs in rhabdomyosarcoma and neuroblastoma and translational perspectives. *International Journal of Molecular Sciences*, **2012**, 13, 16554-79	6.3	9
36	Major histocompatibility complex class i and tumour immuno-evasion: how to fool T cells and natural killer cells at one time. *Current Oncology*, **2012**, 19, 39-41	2.8	29
35	ERAAP modulation: A possible novel strategy for cancer immunotherapy?. *OncoImmunology*, **2012**, 1, 81-82	7.2	4
34	Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy. *International Journal of Oncology*, **2012**, 41, 117-24	4.4	4
33	IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma. *PLoS ONE*, **2012**, 7, e46928	3.7	43
32	Human hepatic stellate cells are liver-resident antigen-presenting cells. *Hepatology*, **2011**, 54, 1107	11.2	4
31	Natural killer cells efficiently reject lymphoma silenced for the endoplasmic reticulum aminopeptidase associated with antigen processing. *Cancer Research*, **2011**, 71, 1597-606	10.1	58
30	NF-kappaB, and not MYCN, regulates MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cells. *Cancer Research*, **2010**, 70, 916-24	10.1	47
29	HLA-E and the origin of immunogenic self HLA epitopes. *Molecular Immunology*, **2010**, 47, 1661-2; author reply 1163-4	4.3	5
28	Class I HLA folding and antigen presentation in beta 2-microglobulin-defective Daudi cells. *Journal of Immunology*, **2009**, 182, 3609-17	5.3	18
27	Genetic risk factors in typical haemolytic uraemic syndrome. *Nephrology Dialysis Transplantation*, **2009**, 24, 1851-7	4.3	18
26	N-linked glycosylation selectively regulates the generic folding of HLA-Cw1. *Journal of Biological Chemistry*, **2008**, 283, 16469-76	5.4	6
25	Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non-lymphoid human tissues. *Journal of Cellular Physiology*, **2008**, 216, 742-9	7	73
24	Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. *PLoS ONE*, **2008**, 3, e2236	3.7	312
23	Expression of endoplasmic reticulum aminopeptidases in EBV-B cell lines from healthy donors and in leukemia/lymphoma, carcinoma, and melanoma cell lines. *Journal of Immunology*, **2006**, 176, 4869-79	5.3	77
22	Effect of the [CCTG]n repeat expansion on ZNF9 expression in myotonic dystrophy type II (DM2). *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2006**, 1762, 329-34	6.9	36

21	Assembly and selective "in synthesis" labeling of quenched fluorogenic protease substrates. *Analytical Biochemistry*, **2006**, 357, 194-9	3.1	6
20	Impaired assembly results in the accumulation of multiple HLA-C heavy chain folding intermediates. *Journal of Immunology*, **2005**, 175, 6651-8	5.3	10
19	Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. *Nature Immunology*, **2005**, 6, 689-97	19.1	361
18	Angiotensin-converting enzyme (ACE) haplotypes and cyclosporine A (CsA) response: a model of the complex relationship between ACE quantitative trait locus and pathological phenotypes. *Human Molecular Genetics*, **2005**, 14, 2357-67	5.6	7
17	Control of cross-presentation during dendritic cell maturation. *European Journal of Immunology*, **2004**, 34, 398-407	6.1	121
16	Quantifying recruitment of cytosolic peptides for HLA class I presentation: impact of TAP transport. *Journal of Immunology*, **2003**, 170, 2977-84	5.3	46
15	Beyond the proteasome: trimming, degradation and generation of MHC class I ligands by auxiliary proteases. *Molecular Immunology*, **2002**, 39, 203-15	4.3	62
14	Efficient MHC class I-independent amino-terminal trimming of epitope precursor peptides in the endoplasmic reticulum. *Immunity*, **2001**, 15, 467-76	32.3	68
13	Linkage analysis of multiple sclerosis with candidate region markers in Sardinian and Continental Italian families. *European Journal of Human Genetics*, **1999**, 7, 377-85	5.3	34
12	Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3. *International Journal of Cancer*, **1996**, 68, 622-8	7.5	24
11	Differences in peptide-binding specificity of two ankylosing spondylitis-associated HLA-B27 subtypes. *Immunogenetics*, **1995**, 42, 123-8	3.2	10
10	Augmentation of the affinity of HLA class I-binding peptides lacking primary anchor residues by manipulation of the secondary anchor residues. *Journal of Peptide Science*, **1995**, 1, 266-73	2.1	7
9	The peptide binding specificity of HLA-B27 subtypes. *Immunogenetics*, **1994**, 40, 192-8	3.2	32
8	Exploring myelin basic protein for HLA class I-binding sequences. *European Journal of Immunology*, **1994**, 24, 2196-202	6.1	7
7	The peptide-binding specificity of HLA-B27 subtype (B*2705) analyzed by the use of polyalanine model peptides. *Human Immunology*, **1994**, 41, 34-8	2.3	11
6	HLA-A2-binding peptides cross-react not only within the A2 subgroup but also with other HLA-A-locus allelic products. *Human Immunology*, **1994**, 39, 155-62	2.3	32
5	The importance of secondary anchor residue motifs of HLA class I proteins: a chemometric approach. *Molecular Immunology*, **1994**, 31, 549-54	4.3	27
4	Unfolded HLA class I alpha chains and their use in an assay of HLA class-I-peptide binding. *Human Immunology*, **1993**, 36, 119-27	2.3	19

3	Anchor residue motifs of HLA class-I-binding peptides analyzed by the direct binding of synthetic peptides to HLA class I alpha chains. *Human Immunology*, **1993**, 38, 187-92	2.3	21
2	HLA class I binding of synthetic nonamer peptides carrying major anchor residue motifs of HLA-B27 (B*2705)-binding peptides. *Immunogenetics*, **1993**, 38, 41-6	3.2	19
1	Global changes in gene expression in Escherichia coli K12 induced by bacteriophage Mu Gem protein. *Research in Microbiology*, **1991**, 142, 13-21	4	3